Ribavirin, another HCV antiviral, decreased glioma cell growth and migration in vitro by targeting the eukaryotic initiation factor, EZH2, and extracellular signal-regulated kinase (ERK) pathways [58]. The gene discussed is EZH2; the disease is central nervous system cancer.